Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 228   

Articles published

SNY 48.08 -0.21 (-0.43%)
price chart
Eli Lilly and Co Poses Threat To Sanofi SA (ADR) With Biosimilar Insulin
Eli Lilly & Co announced yesterday it is ready to launch Abasria, a cheaper biosimilar version of Sanofi's blockbuster diabetic drug, Lantus.
Sanofi (SNY) Stock: One Big Bet on Diabetes Drugs  Investorplace.com
Sanofi SA (ADR) (NYSE:SNY) can sell Lantus: approved by US  Investor Wired
Sanofi SA (ADR) New CEO To Focus On US Market
Sanofi's quest to find a replacement for ousted CEO Chris Viehbacher has come to an end. It finally announced Thursday the appointment of Olivier Brandicourt, head of Bayer AG's (ADR)(OTCMKTS:BAYRY) healthcare business, as its new CEO.
Stocks Red-Hot After News: Sanofi SA (ADR) (NYSE:SNY), Vale SA (ADR ...  Investor Wired (press release)
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
Sanofi SA (ADR) (SNY) Launches Inhaled Insulin Afrezza
Sanofi SA (ADR) (NYSE:SNY) has launched its inhalable insulin Afrezza in the US, the company announced before the US markets opened for trading Tuesday.
Analyst Rating Update on Sanofi SA (ADR)
Analysts at Zacks have given a short term rating of sell on Sanofi-Aventis Sa (NYSE:SNY) with a rank of 4. The counter has received an average rating of 2.2 from 5 brokerage firms.
Zacks Long Term Rating Update on Sanofi SA (ADR)
As much as 5 analysts have advised buy on Sanofi SA (ADR) (NYSE:SNY) with an average broker rating of 2.2. Zacks research analysts are highly pessimistic on the counter and has given it a short term rating of 5, indicating that it is a Underperform ...
Company Shares of Sanofi SA (ADR) Rally 1.38%  Ashburn Daily
Sanofi SA (ADR) (NYSE:SNY) Update: Sanofi upgraded to Buy from Neutral at ...  Rock Hill Daily
Sanofi SA (SNY) Q4 Earnings Preview
Sanofi SA (ADR) (NYSE:SNY) is scheduled to announce its financial results for the fourth quarter of fiscal year 2014 (4QFY14) on Thursday, February 5 before the market opens.
Zacks Rating Disclosure on Sanofi SA (ADR)  Wall Street Pulse
Shares of Sanofi SA (ADR) Sinks by -1.69% for the Week  Winston View
First Call Recommends Buy on Sanofi SA (ADR)
Sanofi SA (ADR) (NYSE:SNY): First Call has rated the counter a Buy. The rating recommendation was disclosed in the First Call research information.
Company Shares of Sanofi SA (ADR) Rally 4.25%  Ashburn Daily
Sanofi SA (ADR) Witness Inflow of Net $1.65M  Markets Bureau
Sanofi SA (ADR) Analyst Rating Update
Research firm Zacks has rated Sanofi SA (ADR) (NYSE:SNY) and has ranked it at 5, indicating that its shares are a Underperform.
Sanofi SA (ADR) Price Target Update  Bar and Graph Report
Share Price of Sanofi SA (ADR) Rally 2.85%  Winston View
Cerdelga by Genzyme Corporation of Sanofi SA (ADR) (NYSE:SNY)
Genzyme Corporation, which is a biotechnology company based in Massachusetts and a subsidiary of Sanofi SA (ADR) (NYSE:SNY), made it public that it has developed a drug as a cure for type 1 of Gaucher disease (GD1).